Our results also suggest that in addition to inhibiting the downstream PI3K target mTOR in LECs, the immune suppressive effect of rapamycin affecting both myeloid and lymphoid cells may contribute to its therapeutic benefit in the treatment of LM. Here, PIK3CA is linked to lymphangioma.